Casdin Capital, LLC — 13F Holdings & Portfolio

CIK 1534261 · latest 13F-HR filed 2026-08-14

Casdin Capital, LLC manages $2.00B in 13F-reported U.S. long-equity assets across 43 reported positions as of its 2026-06-30 13F-HR filing. Its largest disclosed positions are RVMD (24.16%), RLAY (15.02%), WGS (12.74%). Quarter over quarter (versus its 2026-03-31 filing) the fund opened 6 new positions and exited 3; 32 existing positions rose in reported value and 4 fell.

AUM is the long-equity portion reported on Form 13F-HR. Excludes short positions, cash, foreign holdings, and non-13F assets. For informational purposes only — not investment advice.

Loading holdings…
AUM
$2.00B

Long-equity book

Holdings
43

Distinct positions

Period
2026-06-30

Filed 2026-08-14

Q/Q Activity
+6 / −3 / ↑32 / ↓4

vs 2026-03-31

Portfolio charts

Latest quarter's book, what changed, and how the portfolio has evolved across filings.

Portfolio map

Q2 26

Box size = position value; colour = change in share count vs the prior quarter (green added, red trimmed, blue new). Rows split across managers or share classes are combined. Click a box for the stock.

Sector mix

% of 13F value

Sectors from each company's SIC code; funds and ETFs grouped separately.

Biggest buys and sells

Q1 26 → Q2 26

Estimated from the change in shares held × the quarter-end price, so price moves alone don't count as buying. New and exited positions are included.

13F assets and positions

4 quarters

Total reported 13F value (bars) and number of positions (line) each quarter. Value changes include market moves.

Top positions over time

reported value

The eight largest current positions, valued at each quarter end.

Concentration

top 10 = 77.4%

Cumulative share of the portfolio held in the largest N positions.

Firm Profile & Key People

As of the firm’s regulatory filing dated Mar 31, 2026.

Assets Under Management
$2.87B
Discretionary
$2.87B
Employees
29
Accounts
7
Address
1350 AVENUE OF THE AMERICAS
SUITE 2600
NEW YORK, NY 10019
Phone
(212) 897-5430
Name Title / Status Ownership Type
CANZONERI, LAWRENCE, JUDE ControlCHIEF FINANCIAL OFFICER
since May 2019
Less than 5%Individual
CASDIN, ELI, D ControlMANAGING MEMBER
since Aug 2011
75% or moreIndividual
CRUPI, ANGELO ControlCHIEF COMPLIANCE OFFICER
since Mar 2021
Less than 5%Individual
FISK, ALEXANDRIA ControlCHIEF OPERATING OFFICER
since Jan 2020
Less than 5%Individual
GIORDANO, STEVEN, MICHAEL ControlGENERAL COUNSEL
since Mar 2022
Less than 5%Individual
Ownership & leadership changes · 9 filings with changes since Nov 20, 2013

From the firm’s regulatory filings, newest first. Dates are filing dates: a filing that no longer lists someone does not say when they left.

Mar 31, 2022 filing
  • No longer listedO'BRIEN, KEVIN, EUGENE · CHIEF LEGAL OFFICER · Less than 5% · control person · listed since Mar 2018
  • AddedGIORDANO, STEVEN, MICHAEL · GENERAL COUNSEL · Less than 5% · control person
Mar 29, 2021 filing
  • AddedCRUPI, ANGELO · CHIEF COMPLIANCE OFFICER · Less than 5% · control person
  • ChangedO'BRIEN, KEVIN, EUGENE · title CHIEF COMPLIANCE OFFICER → CHIEF LEGAL OFFICER
Mar 29, 2020 filing
  • No longer listedAPEADU, EVANS · CHIEF FINANCIAL OFFICER · Less than 5% · control person · listed since Jul 2016
  • AddedCANZONERI, LAWRENCE, JUDE · CHIEF FINANCIAL OFFICER · Less than 5% · control person
  • AddedFISK, ALEXANDRIA · CHIEF OPERATING OFFICER · Less than 5% · control person
Mar 28, 2018 filing
  • AddedO'BRIEN, KEVIN, EUGENE · CHIEF COMPLIANCE OFFICER · Less than 5% · control person
  • ChangedAPEADU, EVANS · title CHIEF COMPLIANCE OFFICER AND CHIEF FINANCIAL OFFICER → CHIEF FINANCIAL OFFICER
Jul 11, 2017 filing
  • ChangedCASDIN, ELI, D · title MANAGER → MANAGING MEMBER
Jun 27, 2017 filing
  • ChangedAPEADU, EVANS · title CHIEF FINANCIAL OFFICER → CHIEF COMPLIANCE OFFICER AND CHIEF FINANCIAL OFFICER
Mar 31, 2017 filing
  • No longer listedEHRHART, MATTHEW, EVAN · CHIEF FINANCIAL OFFICER · Less than 5% · control person · listed since Mar 2014
  • AddedAPEADU, EVANS · CHIEF FINANCIAL OFFICER · Less than 5% · control person
Mar 18, 2016 filing
  • ChangedEHRHART, MATTHEW, EVAN · title DIRECTOR OF FINANCE → CHIEF FINANCIAL OFFICER
Mar 27, 2015 filing
  • No longer listedSHIM, BRIAN, KISUNG · CHIEF COMPLIANCE OFFICER · Less than 5% · control person · listed since Aug 2011
  • AddedEHRHART, MATTHEW, EVAN · DIRECTOR OF FINANCE · Less than 5% · control person
Nov 20, 2013 filing (earliest on record)
  • ListedCASDIN, ELI, D · MANAGER · 75% or more · control person
  • ListedSHIM, BRIAN, KISUNG · CHIEF COMPLIANCE OFFICER · Less than 5% · control person

Quarter-over-quarter changes

Changes in reported position value vs the prior 13F, so price moves count too, not just shares bought or sold.

Casdin Capital, LLC Holdings (2026-06-30)

Rows tagged Call or Put are options positions, not stock. Per SEC Form 13F-HR, Value shows the notional value of the underlying (shares covered × underlying price), not the option premium. Shares is the number of underlying shares covered (divide by 100 for contract count).

# Issuer Symbol CUSIP Value Weight Shares Type
1 REVOLUTION MEDICINES INC RVMD 76155X100 $482.7M 24.16% 2,577,333 SH
2 RELAY THERAPEUTICS INC RLAY 75943R102 $300.0M 15.02% 16,035,240 SH
3 GENEDX HOLDINGS CORP WGS 81663L200 $254.5M 12.74% 3,707,164 SH
4 BIOLIFE SOLUTIONS INC BLFS 09062W204 $131.5M 6.58% 4,655,000 SH
5 ILLUMINA INC ILMN 452327109 $93.2M 4.66% 530,000 SH
6 STANDARD BIOTOOLS INC LAB 34385P108 $73.0M 3.66% 88,783,856 SH
7 STRUCTURE THERAPEUTICS INC GPCR 86366E106 $63.1M 3.16% 1,175,000 SH
8 DENALI THERAPEUTICS INC DNLI 24823R105 $52.6M 2.63% 2,045,000 SH
9 NEUROGENE INC NGNE 64135M105 $48.6M 2.43% 1,545,361 SH
10 BEAM THERAPEUTICS INC BEAM 07373V105 $46.3M 2.32% 1,350,000 SH
11 10X GENOMICS INC TXG 88025U109 $40.3M 2.02% 1,050,000 SH
12 SCHOLAR ROCK HLDG CORP SRRK 80706P103 $36.6M 1.83% 665,000 SH
13 PERSONALIS INC PSNL 71535D106 $34.2M 1.71% 2,550,000 SH
14 GRAIL INC GRAL 384747101 $32.8M 1.64% 480,000 SH
15 GUARDANT HEALTH INC GH 40131M109 $27.8M 1.39% 185,000 SH
16 MAZE THERAPEUTICS INC MAZE 578784100 $25.2M 1.26% 843,857 SH
17 HIMS & HERS HEALTH INC HIMS 433000106 $24.3M 1.21% 700,000 SH
18 ALNYLAM PHARMACEUTICALS INC ALNY 02043Q107 $22.6M 1.13% 75,000 SH
19 TAYSHA GENE THERAPIES INC TSHA 877619106 $22.1M 1.11% 3,250,000 SH
20 AGOMAB THERAPEUTICS NV AGMB 00860C102 $20.1M 1.01% 1,550,000 SH
21 SEPTERNA INC SEPN 81734D104 $18.5M 0.93% 553,268 SH
22 PARABILIS MEDICINES INC PBLS 698955101 $17.7M 0.88% 645,690 SH
23 SIONNA THERAPEUTICS INC SION 829401108 $17.6M 0.88% 400,000 SH
24 VERACYTE INC VCYT 92337F107 $16.2M 0.81% 276,308 SH
25 ADLAI NORTYE LTD ANL 00704R109 $14.4M 0.72% 1,250,000 SH
26 PRIME MEDICINE INC PRME 74168J101 $11.7M 0.58% 3,167,175 SH
27 ABSCI CORPORATION ABSI 00091E109 $11.3M 0.56% 973,260 SH
28 QUEST DIAGNOSTICS INC DGX 74834L100 $10.6M 0.53% 50,000 SH
29 SAREPTA THERAPEUTICS INC SRPT 803607100 $8.4M 0.42% 470,000 SH
30 UNIQURE NV QURE N90064101 $6.9M 0.35% 150,000 SH
31 INTELLIA THERAPEUTICS INC NTLA 45826J105 $6.0M 0.30% 355,000 SH
32 MODERNA INC MRNA 60770K107 $5.3M 0.26% 75,000 SH
33 DISC MEDICINE INC IRON 254604101 $4.8M 0.24% 65,000 SH
34 MONTE ROSA THERAPEUTICS INC GLUE 61225M102 $4.5M 0.23% 186,014 SH
35 CENTURY THERAPEUTICS INC IPSC 15673T100 $3.0M 0.15% 1,228,190 SH
36 CONTINEUM THERAPEUTICS INC CTNM 21217B100 $2.4M 0.12% 148,333 SH
37 BRIDGEBIO ONCOLOGY THERAPEUT BBOT 107924102 $2.2M 0.11% 282,312 SH
38 EDITAS MEDICINE INC EDIT 28106W103 $1.4M 0.07% 445,000 SH
39 PACIFIC BIOSCIENCES CALIF IN PACB 69404D108 $1.2M 0.06% 723,767 SH
40 KARDIGAN INC KARD 485925101 $1.2M 0.06% 50,000 SH
41 RECURSION PHARMACEUTICALS IN RXRX 75629V104 $606.7K 0.03% 165,323 SH
42 GINKGO BIOWORKS HOLDINGS INC DNA 37611X209 $361.6K 0.02% 36,493 SH
43 TENAYA THERAPEUTICS INC TNYA 87990A106 $267.5K 0.01% 361,969 SH
Filing History
Period Filed AUM Holdings Accession
2026-06-30 2026-08-14 $2.00B 43 0000919574-26-005491
2026-03-31 2026-05-15 $1.32B 40 0000919574-26-003451
2025-12-31 2026-02-17 $1.61B 38 0000919574-26-001181
2025-09-30 2025-11-14 $1.20B 32 0000919574-25-007006
Filer Information
Address
1350 AVENUE OF THE AMERICAS
SUITE 2600
NEW YORK, NY 10019
Phone
(212) 554-4952
Filing Manager
Casdin Capital, LLC
New York, NY
Signatory
Steve Giordano
General Counsel